课题基金 / 基金详情

PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MINOCYCLINE IN T

PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MINOCYCLINE IN T
米诺环素治疗 T 细胞的 II 期、随机、安慰剂对照、双盲研究
批准号:
8167100
负责人:
ARDIS A MOE
金额:
$6.87万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-12-01 至 2010-11-30

项目摘要

项目成果

ARDIS A MOE的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary Objective " To examine whether minocycline treatment for 24 weeks improves HIV-associated cognitive impairment. Secondary Objectives " To examine whether minocycline treatment for 24 weeks is safe and well-tolerated in individuals with HIV-associated cognitive impairment. " To examine whether minocycline treatment for 48 weeks is safe and well-tolerated in individuals with HIV-associated cognitive impairment. " To examine whether minocycline treatment for 24 weeks improves functional impairment. " To examine whether minocycline treatment for 24 weeks decreases levels of several markers of HIV-associated cognitive impairment including, but not limited to, HIV-1 RNA; a marker of immune activation, [monocyte chemoattractant protein (MCP-1)]; a marker of apoptosis (sFas); markers of oxidative stress [ceramide, sphingomyelin, 4-hydroxynonenal (HNE), and 3-nitrotyrosine [3-NT] modified proteins] in blood and cerebrospinal fluid (CSF).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI
SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV
A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR WITH RI
A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF A QUADRIVALENT HUM
海外基金